Dansk bioteknologisk firma, Zealand Pharma, oplever en enorm stigning i aktiekursen efter lovende resultater fra vægttabsbehandlinger.
Zealand Pharma har oplevet en eksplosiv stigning på 32% efter lovende resultater fra fase 2 forsøg på et lægemiddel, der kan behandle både leversygdomme og fedme. Analytikere betegner Zealand Pharma's fase 2 forsøg som en "ubestridelig sejr". Konkurrencen mod Novo Nordisk og Eli Lilly intensiveres, da flere virksomheder ser muligheder i vægttabsmedicinens guldfeber. Zealand Pharma blevet opgraderet af JPMorgan-analytikere, og deler skyhøjt i København efter stærke forsøgsresultater for deres vægttabbehandlinger. Et lovende gennembrud i behandlingen af leverfedt kan være på vej med Zealand Pharma's eksperimentelle vægttabslægemiddel i samarbejde med Boehringer Ingelheim. Altimmune's aktie oplevede en markant stigning efter Zealand Pharma's positive fase 2 forsøgsresultater for survodutide.
Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.
The competition against Novo Nordisk and Eli Lilly is heating up as several companies look to get in on on the weight loss drug gold rush.
Danish biotechnology research company Zealand Pharma A/S (CSE:ZELA) (ZLDPF) saw its shares soar more than 35% in Copenhagen on Monday after following ...
Promising mid-stage trial results for an experimental weight-loss drug by Zealand Pharma and Boehringer Ingelheim could mark a breakthrough in treating ...
Zealand Pharma (ZEAL.CO) stock skyrockets on positive results from a liver disease treatment trial. JPMorgan analysts upgrade retailer The Gap (GPS) to ...
Shares in Zealand Pharma jumped 22% on Monday after an experimental drug it is developing with Boehringer Ingelheim yielded "groundbreaking" mid-stage trial ...
Discover how Altimmune's stock witnessed a significant surge after Zealand Pharma's positive Phase 2 clinical trial results for survodutide, ...
Pharma: Seeking to challenge obesity treatment market leaders Novo Nordisk and Eli Lilly, Zealand and unlisted Boehringer in June 2023 reported promising ...